We are live on ! Find out more
INDP icon

Indaptus Therapeutics
INDP

18 hedge funds and large institutions have $540K invested in Indaptus Therapeutics in 2024 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

13% more funds holding

Funds holding: 16 → 18 (+2)

0.02% less ownership

Funds ownership: 0.21% → 0.19% (-0.02%)

28% less capital invested

Capital invested by funds: $750K → $540K (-$211K)

Holders
18
Holders Change
+2
Holders Change %
+12.5%
% of All Funds
0.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
4
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$20.2K
2
TSS
Two Sigma Securities
New York
+$18.9K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$10.2K
4
UBS Group
UBS Group
Switzerland
+$2.25K
5
Renaissance Technologies
Renaissance Technologies
New York
+$667

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$19.1K
2
TRCT
Tower Research Capital (TRC)
New York
-$1.49K
3
PVI
Pine Valley Investments
New Jersey
-$64
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$216K – – –
IHL
2
Investment House LLC
California
$84.4K +$222 +7 +0.2%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$69.2K +$10.2K +321 +12%
SAM
4
Strategy Asset Managers
California
$38.2K – – –
PVI
5
Pine Valley Investments
New Jersey
$37K -$64 -2 -0.1%
Renaissance Technologies
6
Renaissance Technologies
New York
$23.3K +$667 +21 +2%
VCM
7
Vivaldi Capital Management
Illinois
$22.2K – – –
Susquehanna International Group
8
Susquehanna International Group
Pennsylvania
$15K +$20.2K +637 New
TSS
9
Two Sigma Securities
New York
$14K +$18.9K +594 New
State Street
10
State Street
Massachusetts
$11K – – –
SS
11
SBI Securities
Japan
$3.28K +$4.41K +139 New
TRCT
12
Tower Research Capital (TRC)
New York
$2.96K -$1.49K -47 -27%
UBS Group
13
UBS Group
Switzerland
$2.12K +$2.25K +71 +374%
Morgan Stanley
14
Morgan Stanley
New York
$744 – – –
BSB
15
Bangor Savings Bank
Maine
$337 – – –
Wells Fargo
16
Wells Fargo
California
$54 – – –
Bank of America
17
Bank of America
North Carolina
$51 – – –
JP Morgan Chase
18
JP Morgan Chase
New York
$16 – – –
Group One Trading
19
Group One Trading
Illinois
$6 – – –
DB
20
Danske Bank
Denmark
$1 – – –
Citadel Advisors
21
Citadel Advisors
Florida
– -$19.1K -550 Closed

INDP Hedge Fund Activity: Q4 2024 in Review

18 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q4 2024, worth a combined $540K — down 28% from $750K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new INDP positions and 1 closed out — a net gain of 2 holders — while 4 added to existing stakes and 2 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $20.2K. The largest seller was Citadel Advisors, exiting entirely with an estimated $19.1K sold.

  • 18 institutional investors held Indaptus Therapeutics (INDP) as of Q4 2024, up from 16 in Q3 2024.
  • Funds reported $540K of Indaptus Therapeutics stock for Q4 2024, down 28% quarter-over-quarter.
  • 3 funds opened new Indaptus Therapeutics positions in Q4 2024 and 1 closed out, a net change of +2 holders.
  • The largest Indaptus Therapeutics buyer in Q4 2024 was Susquehanna International Group, an estimated $20.2K added.
  • The largest Indaptus Therapeutics seller in Q4 2024 was Citadel Advisors, an estimated $19.1K sold.

Based on aggregated 13F filings for Q4 2024.